Literature DB >> 8960062

Model for estimating dopamine transporter occupancy and subsequent increases in synaptic dopamine using positron emission tomography and carbon-11-labeled cocaine.

S J Gatley1, N D Volkow, A N Gifford, Y S Ding, J Logan, G J Wang.   

Abstract

Although increases in dopamine secondary to the inhibition of the dopamine transporter appear to underlie the reinforcing properties of cocaine, there is presently no model that relates the elevation of synaptic dopamine to the transporter occupancy by cocaine. We propose such a model based on positron emission tomographic (PET) measurements of the brain concentration of cocaine and the assumption of rapid equilibrium between free cocaine and cocaine bound to the dopamine transporter. A euphorigenic dose of cocaine (about 40 mg) is predicted to occupy 80-90% of the transporters, while a perceptible dose (about 5 mg) occupies about 40% of the transporters. If reuptake of dopamine is reduced in proportion to the fraction of transporters occupied by cocaine, our model indicates that synaptic dopamine rises supra-linearly with occupancy, so that 5 and 40 mg doses of cocaine give about 2- and 10-fold increases, respectively. A consequence is that a given dose of cocaine produces a similar degree of elevation of dopamine regardless of the prior level of occupation of the transporters by cocaine. This prediction is supported by recent PET/neuropsychological studies in our laboratory where dopamine transporter occupancy was measured after giving methylphenidate intravenously to volunteers; similarly intense "highs" were reported whether the initial occupancy was zero or 75-85%. It could also explain why attempts to block the psychostimulant-induced "high" by pretreating subjects with drugs that block the dopamine transporter have been unsuccessful, and why the use of methylphenidate to treat cocaine addicts led to increased cocaine consumption.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8960062     DOI: 10.1016/s0006-2952(96)00655-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

Review 1.  Current concepts in pharmacotherapy of substance abuse.

Authors:  P C Gottschalk; L K Jacobsen; T R Kosten
Journal:  Curr Psychiatry Rep       Date:  1999-12       Impact factor: 5.285

Review 2.  Neuroimaging in drug abuse.

Authors:  Kimberly P Lindsey; S John Gatley; Nora D Volkow
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

3.  Smoking produces rapid rise of [11C]nicotine in human brain.

Authors:  Marc S Berridge; Scott M Apana; Kenichi K Nagano; Catherine E Berridge; Gregory P Leisure; Mark V Boswell
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

4.  Developmental pesticide exposure reproduces features of attention deficit hyperactivity disorder.

Authors:  Jason R Richardson; Michele M Taylor; Stuart L Shalat; Thomas S Guillot; W Michael Caudle; Muhammad M Hossain; Tiffany A Mathews; Sara R Jones; Deborah A Cory-Slechta; Gary W Miller
Journal:  FASEB J       Date:  2015-01-28       Impact factor: 5.191

5.  Increased Sensitivity to Cocaine Self-Administration in HIV-1 Transgenic Rats is Associated with Changes in Striatal Dopamine Transporter Binding.

Authors:  Scot McIntosh; Tammy Sexton; Lindsey P Pattison; Steven R Childers; Scott E Hemby
Journal:  J Neuroimmune Pharmacol       Date:  2015-03-10       Impact factor: 4.147

Review 6.  DARK Classics in Chemical Neuroscience: Cocaine.

Authors:  Lindsey R Drake; Peter J H Scott
Journal:  ACS Chem Neurosci       Date:  2018-04-24       Impact factor: 4.418

7.  Measurement of psychological state changes at low dopamine transporter occupancy following a clinical dose of mazindol.

Authors:  Y Kimura; J Maeda; M Yamada; K Takahata; K Yokokawa; Y Ikoma; C Seki; H Ito; M Higuchi; T Suhara
Journal:  Psychopharmacology (Berl)       Date:  2016-10-20       Impact factor: 4.530

8.  Reinforcing Doses of Intravenous Cocaine Produce Only Modest Dopamine Uptake Inhibition.

Authors:  Zachary D Brodnik; Mark J Ferris; Sara R Jones; Rodrigo A España
Journal:  ACS Chem Neurosci       Date:  2016-12-29       Impact factor: 4.418

9.  Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis.

Authors:  Benjamin B Gelman; Jeffrey A Spencer; Charles E Holzer; Vicki M Soukup
Journal:  J Neuroimmune Pharmacol       Date:  2006-08-08       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.